Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
Mind Medicine Inc. ($MNMD) announced an update on their ongoing clinical study. Study Overview Mind Medicine Inc. (MNMD) is running a Phase 2a ...
On Saturday April 5, Anavex announced data from their open-label extension trial, ATTENTION-AD, for early Alzheimer's Disease presented at the AD/PDTM 2025 Conference. ATTENTION-AD is a follow-on ...
Biontech Se Sponsored Adr (BNTX), Genmab (Otc) (GMAB) announced an update on their ongoing clinical study.
A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...
Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non–Small-Cell Lung Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback